Biofourmis Raises Additional Funding From Intel Capital In Series D Extension And Names Top Healthcare Leaders To Its Board
Aug 10, 2022•about 3 years ago
Round Type
series d
Description
Biofourmis, a Boston-based global leader in virtual care and digital medicine, today announced that Intel Capital, the strategic investment arm of chipmaker Intel Corporation, has joined its Series D financing in an extension that brings the total funding raised in the round to $320M. The initial Series D funding round was announced in April and was led by global growth equity firm General Atlantic with participation by CVS Health (NYSE:CVS), Trevor Fetter and existing investors.